UNSPSC 51111630: Decitabine

This classification denotes a fbxw4 gene with the molecular formula C8H12N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 776B62CQ27, chemically known as 1,3,5-triazin-2(1h)-one, 4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)- but generally known as decitabine, which bears US NIH Compound Identifier 16886. European Medicines Agency schedules Decitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06932MIG.

UNSPSC 51111630 Decitabine is a Commodity code identifying a specific pharmaceutical product — a DNA methyltransferase inhibitor used primarily in the treatment of myelodysplastic syndromes and certain hematologic malignancies. State and local governments procure decitabine through their health departments, correctional systems, public hospitals, and health agencies as part of formulary management and inpatient oncology treatment protocols. Purchasing typically occurs through group purchasing organizations, state Medicaid programs, and cooperative pharmaceutical procurement vehicles rather than direct competitive solicitation, though individual health systems and prison medical services occasionally issue RFQs for pharmaceutical supply contracts. The code reflects commodity-level pharmaceutical procurement aligned with federal pricing benchmarks such as the average manufacturer price and statutory rebate programs under Medicaid.

The source provides no recent state or local contract opportunities tagged to this code, precluding characterization of active issuing bodies, geographic concentration, or representative recent solicitations. Decitabine procurement at the state and local level operates largely through established group purchasing and Medicaid reimbursement frameworks rather than through posted RFPs, RFQs, or ITBs, making visibility into individual jurisdictional buying activity limited in public notice channels.